HC Wainwright & Co. Reiterates Buy on Mainz Biomed, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Mainz Biomed (NASDAQ:MYNZ) but lowered the price target from $10 to $7.

August 18, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mainz Biomed's price target has been lowered from $10 to $7 by HC Wainwright & Co., although the 'Buy' rating has been maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term negative sentiment among investors, which might put downward pressure on the stock price. However, the reiteration of the 'Buy' rating indicates that the analyst still sees potential in the company, which could offset some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100